UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000010395 |
|---|---|
| Receipt number | R000012160 |
| Scientific Title | Clinical effect of everolimus and somatostatin analogues as a first line therapy for patients with pNET (phase II study) |
| Date of disclosure of the study information | 2013/04/08 |
| Last modified on | 2019/10/07 14:50:22 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Clinical effect of everolimus and somatostatin analogues as a first line therapy for patients with pNET (phase II study)
Acronym
Clinical effect of everolimus and somatostatin analogues for patients with pNET
Scientific Title
Clinical effect of everolimus and somatostatin analogues as a first line therapy for patients with pNET (phase II study)
Scientific Title:Acronym
Clinical effect of everolimus and somatostatin analogues for patients with pNET
Region
| Japan |
Condition
Condition
Patients with unresectable or metastatic pNET
Classification by specialty
| Hepato-biliary-pancreatic surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To investigate clinical efficacy and sefety of evelolimus and somatostatin analogue for patients with unresectabel pNET
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
progression free survival
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Combined therapy of evelrolimus and somatostatin analogue
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1.pathologically proved NET
2.unresectable disease
3.no prior therapy
4.ECOG performance status 0-2
5.target lesion on RECIST
6.Adequate organ function
7.Written informed consent
Key exclusion criteria
1.past history of allergy for everolimus or somatostatin analogue
2.inaduquate organ function
3.steroids or immunosuppressive thrapy
4.Pregnant females, possibly pregnant females
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Sohei SATOI |
Organization
Kansai Medical University
Division name
Department of Surgery
Zip code
Address
2-3-1 Shinmachi, Hirakata, Osaka
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name |
Organization
Kansai Medical University
Division name
Department of Surgery
Zip code
Address
TEL
Homepage URL
satoi@hirakata.kmu.ac.jp
Sponsor or person
Institute
Kansai Medical University
Institute
Department
Personal name
Funding Source
Organization
Department of Surgery, Kansai Medical University
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 04 | Month | 08 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Terminated
Date of protocol fixation
| 2013 | Year | 04 | Month | 01 | Day |
Date of IRB
| 2013 | Year | 04 | Month | 01 | Day |
Anticipated trial start date
| 2013 | Year | 04 | Month | 08 | Day |
Last follow-up date
| 2019 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2013 | Year | 04 | Month | 02 | Day |
Last modified on
| 2019 | Year | 10 | Month | 07 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012160
